Long-Acting and Innovative Formulations and Drug Delivery Devices: Possibilities for Children and Adolescents - Charles Flexner, MD

International Workshop on HIV & Pediatrics 2019

Host-microbiome interactions at the oral mucosal barrier - Niki Moutsopoulos, DDS, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Regulation of intestinal viral infections by the microbiota - Megan Baldridge, MD, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Glycomic Determinants of Gut Microbial Dysbiosis and Translocation During Suppressed HIV Infection - Leila Giron

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Host Genetic Determinants of the Vaginal Microbiome and Bacterial Vaginosis in Kenyan Women - Supriya Mehta

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

ELEVATED FECAL INFLAMMATORY BIOMARKERS IN HIV-/+ MSM ASSOCIATE WITH GUT MICROBIOTA - Jennifer Schneider

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Metaproteomics to understand mucosal inflammation associated with HIV acquisition risk in young African women - Lindi Masson

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Update on live biotherapeutic trials to prevent vaginal dysbiosis and HIV - Craig Cohen, MD, MPH

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Oral Fecal Microbiota Transplantation Increases Gut Microbiome Diversity and Alters the Microbiome Distribution in People with HIV - Netanya Utay, MD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

The relationship between the gut microbiome, inflammation and metabolic disease in HIV infected and high risk populations - Catherine Lozupone

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Endotoxemia, inflammation and HIV: Revisiting an old concept - Jean-Pierre Routy, MD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Microbial therapeutics and opportunities in HIV - Ma Somsouk

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Development of a live biotherapeutic product: Opportunities and challenges - Scott Plevy, MD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2019

Second generation INSTI regimens for drug naive patients: State of the Art - Daniel Kuritzkes, MD

European HIV Clinical Forum 2019

First line regimens in different European countries 2019 – an overview - Miłosz Parczewski, MD, PhD

European HIV Clinical Forum 2019

When to start antiretroviral therapy after diagnosis – trade-offs and considerations - Anton Pozniak, MD, FRCP

European HIV Clinical Forum 2019

Challenges of Long-Term PrEP - Pep Coll, MD

European HIV Clinical Forum 2019

Update on PrEP use in Europe - Ann Sullivan, MBBS, DIPGUM, DFFP, MD, FRCP

European HIV Clinical Forum 2019

Oral Versus Injectable PrEP - Saye Khoo, MD, PhD

European HIV Clinical Forum 2019

New Treatments and Treatment Paradigms - Sharon Walmsley, FRCPC, MD, MSC

European HIV Clinical Forum 2019

Single-Tablet Regimens Versus Multiple Pills: Is There a Meaningful Difference? - Bonaventura Clotet, MD, PhD

European HIV Clinical Forum 2019

Impact on transmitted and acquired drug resistance - Anne-Geneviève Marcelin, PharmD, PhD

European HIV Clinical Forum 2019

Long-Acting Parenteral Antiretroviral Regimens: Where Might They Fit? - Saye Khoo, MD, PhD

European HIV Clinical Forum 2019

Impact on women’s health & weight gain - Laura Waters, MD

European HIV Clinical Forum 2019